Colorectal cancer (CRC) is one of the most common cancers in the Western world. Much has been learned about colorectal cancer from human inherited syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). Mouse models for CRC were generated by introducing mutations into the mouse genes, whose human counterparts were implicated in the onset and progression of CRC. Central among these are mice carrying mutations in the Adenomatous polyposis coli (Apc) gene. Although most of these Apc mutations share some common phenotypes as homozygous embryonic lethality and tumor predisposition, the severity of the tumor predisposition is variable. Mice with mutations in the mismatch repair genes, Msh2 and Mlh1, exhibit a mismatch repair defect and are predisposed to developing gastrointestinal cancer, lymphomas and tumors of other organ systems. Mice carrying a mutation in the Pms2 gene are predisposed to lymphomas and other tumors. Mice with a mutation in the Msh6 gene have a defect in base mismatch repair and show a tumor predisposition phenotype. Mice with mutations in Mlh1, Pms2 and Msh5 have defects in meiosis suggesting unique roles for these genes in gametogenesis.
Keywords: gastrointestinal cancer; FAP; HNPCC; mouse Colorectal cancer (CRC) is one of the most common cancers in the Western hemisphere. In the United States alone, nearly 150 000 new cases of CRC are reported every year and 56 000 deaths are attributed to this cancer. The most frequent form of CRC is sporadic colorectal cancer. Nearly 85% of CRC is sporadic in origin. The second most frequent (5%) cases of colorectal cancer are referred to as hereditary non-polyposis colon cancer (HNPCC). The least frequent form (1/12000) of colorectal cancer is familial adenomatous polyposis (FAP). Several genes that are involved in the initiation and progression of CRC have been identi®ed.
Genetic basis for colorectal cancer
FAP is inherited as an autosomal dominant disorder. Individuals with FAP develop large numbers of adenomas in their colon and rectum during their late teens or early twenties. The adenomas are capable of progressing to carcinomas, become invasive and are capable of producing liver metastases. FAP patients also display extracolonic manifestations, such as congenital hypertrophy of the retinal pigment epithelium, osteomas, medulloblastomas and desmoid tumors of the skin. The gene responsible for FAP has been identi®ed Joslyn et al., 1991; Kinzler et al., 1991) . The gene, designated adenomatous polyposis coli (APC), is located on human chromosome 5. Sporadic colorectal cancer has the same genetic etiology as FAP but the mutations in the APC gene are somatic mutations acquired during the life of an individual. Based on its involvement in FAP and sporadic CRC, the APC gene received much attention.
Although FAP patients have germline mutations in one copy of their APC gene, they do not show any manifestations of the disease until they are older, which in part can be explained by the necessary loss of the WT allele. It was also suggested that APC gene mutation is necessary but not sucient for colon cancer development. Because tumorigenesis is considered to require multiple genetic changes, several eorts to identify other changes in colonic tumors were undertaken. These eorts are continuously revealing the involvement of other genes. Genetic changes in a number of genes including mutated in colorectal cancer (MCC), activation mutations in Ki-RAS/N-RAS, deletion of a region of chromosome 18 containing such as SMAD2, SMAD4 and DCC and mutations in the tumor suppressor TP53 have been described (reviewed in Kinzler and Vogelstein, 1996) .
The human APC gene encodes a 2543 aa protein that contains several functional domains. One of the most critical components of these domains, as far as cancer is concerned, seems to be a domain that is required to bind to b-catenin and to regulate its concentration in the cytoplasm (Su et al., 1993) . bcatenin is a member of the adherence junction (AJ) complex that plays a critical role in transferring extracellular matrix signals to the interior of the cell (reviewed in Bullions and Levine, 1998; Polakis, 1999) . b-catenin is also involved in the Wnt signal transduction pathway. The APC protein, in cooperation with other proteins, e.g. conductin and axin, seems to regulate the free or cytoplasmic form of b-catenin by binding to it and directing it into a protein degradation pathway. Phosphorylation of APC by glycogen synthase kinase 3 beta (GSK3b) in the absence of a Wnt signal or APC gene mutations lead to increased cytoplasmic levels of b-catenin. In this state, b-catenin can migrate to the nucleus and bind to LEF1/TCF-4 transcription factor. This interaction results in the activation of a number of target genes including c-MYC (He et al., 1998) and cyclin D1 (Tetsu and McCormick, 1999) .
Although the biological roles of several genes that are found to be mutated in CRC are well understood, their precise roles in colorectal cancer progression are not well de®ned. This feature is complicated by the fact that not all tumors contain the same set of genetic changes and no clear correlation between the genetic changes and tumor stage have evolved.
Mouse models for colorectal cancer and FAP Dierent FAP families that have the same APC gene mutation may exhibit dierent degrees of severity of the disorder (Burt, 1996) . This observation suggests that other genes may have a modifying eect on FAP. It is also known that environmental factors, especially diet, have an in¯uence on the onset and progression of colorectal cancer. To understand the precise roles of the dierent genes that are found to be mutated in colorectal tumors and to understand the nature of gene-environment interactions, we and others undertook eorts to generate mice that carry mutations in each of several genes implicated in either the initiation or progression of CRC. Table 1 provides a summary of the phenotypes associated with dierent Apc gene mutations.
The ®rst mouse that contained a mutation in the Apc gene was designated multiple intestinal neoplasia (Min) (Su et al., 1992) . This mouse was obtained in an ENU mutagenesis screen. These mice were found to have a nonsense mutation at the region corresponding to codon 850 of the Apc gene. The Min mutation results in a truncated protein of 850 amino acids.
Apc
Min heterozygotes are born normally and have a reduced average lifespan of 150 days. These mice can develop more than 100 adenomas in the small intestine depending on the genetic background.
Many of the human APC gene mutations are located in the last and largest exon, exon 15. In an attempt to mimic human gene mutations, we generated a mutant mouse, designated Apc1638N (Fodde et al., 1994) . In this mouse line, a neomycin expression cassette was inserted at the position corresponding to codon 1638 of the Apc gene in the reverse transcriptional orientation. This mutation results in an unstable 182-kD truncated protein that is dicult to detect by Western blot analysis. Apc1638N heterozygotes progressively develop colonic aberrant crypt foci and polyps and adenomas and carcinomas in the small intestine (Fodde et al., 1994) . These heterozygotes have a longer lifespan of a year or more, perhaps because of the fact that, on average, each mouse develops only 3 ± 5 adenomas/carcinomas of the small intestine . In one case we documented liver metastasis of the gastrointestinal tumor (Fodde et al., 1994) . The Apc1638N animals also display extracolonic manifestations that resemble those of human FAP or Gardners syndrome. These include cutaneous cysts, desmoid tumors and retinal pigment epithelium abnormalities (Marcus et al., 1997; Smits et al., 1998) .
A third allele of Apc, designated Apc716, was also described (Oshima et al., 1995) . Similar to ApcMin mice, mice carrying this mutation develop a large number of gastrointestinal adenomas and have a reduced life span.
Although some of the Apc mutant mice develop colonic polyps, the tumors of the gastrointestinal tract are predominantly found in the small intestine. Use of a conditional Apc allele showed that Apc gene mutations can indeed lead to colonic tumors. The Apc580 allele is a conditional allele, which, when deleted in the colon, leads to adenomas within 4 weeks after the deletion (Shibata et al., 1997) .
The fact that the dierent mutations in the Apc gene exhibit dierent tumor susceptibility phenotypes mirror the heterogeneity seen in human FAP families. The dierences in the severity of the tumor phenotype seem to re¯ect allelic heterogeneity. Another interesting feature of these mutant mice is that, despite the wide variation in tumor phenotypes observed in them, all of these alleles in the homozygous state lead to early embryonic lethality. It is not certain if the cause of lethality in all cases is the same.
Recently Smits et al. (1999) generated a mutation, designated 1638T, at position 1638 of the Apc gene in mice that produces a stable truncated protein. The 182-kD truncated protein still contains some of the bcatenin binding motifs but lacks the carboxy-terminal part of the protein that is necessary for the interaction of APC with other proteins thought to be important for tumorigenesis (e.g. DLG, EB1). On a mixed genetic background, B6/129Ola, homozygosity for the Apc1638T mutation does not result in embryonic lethality but leads to a number of phenotypic abnormalities in adult animals. These include growth retardation, the absence of preputial glands and the formation of nipple-associated cysts. The mutation leads, however, to reduced postnatal survival on a B6 genetic background. These mice show that the absence of a stable APC protein that is capable of proper b- (Shibata et al., 1997) Mouse models for colorectal cancer J Heyer et al catenin regulation is the cause of embryonic failure and is also necessary for the initiation of tumorigenesis. Human colorectal tumors that are the result of APC gene mutations are found to have mutations in other genes. Some of these genes are: mutated in colorectal cancer (MCC), Ki-RAS and N-RAS; deleted in colorectal cancer (DCC), TGF-b signaling pathway members SMAD2 and SMAD4 and TP53 (reviewed in Kinzler and Vogelstein, 1996) . Two dierent approaches were used to examine if mutations in these genes also play an important role in GI tumors from Apc mutant mice. One approach was to examine the tumors from Apc mutant mice for mutations in these genes and the second is the generation of mice with mutations in some of these genes and mate them with the Apc mutant mice and ascertain their in¯uence on tumor susceptibility. When the GI tumors from Apc mutant mice were examined, the only consistent alteration that was observed is the loss of the wild-type copy of the Apc allele through nondisjunction (Figure 1) (Smits et al., 1997; Luongo et al., 1994) . These results indicated that the earliest genetic change during tumor progression is the loss of the wild-type Apc allele and this loss is sucient for progression of the tumor to the adenoma stage. GI tumors of Apc were also examined for K-ras mutations, but no mutations were found (Smits et al., 1997; Shoemaker et al., 1997) .
Combination of Min and p53 leads to pancreatic neoplasia (Clarke et al., 1995) , and the combination of Apc1638N and p53 leads to an increase in desmoid tumors (Smits et al., 1998) . In both studies there was no indication of increased tumor formation in the GI tract.
In human populations, epidemiological studies have shown that environmental factors, especially diet, plays an important role in colon cancer susceptibility. This feature was examined in Apc mutant mice by placing them on low fat, high ®ber diet or high fat with low levels of calcium and vitamin D (Western style diet). It was shown that mice placed on a high fat Western style diet have increased tumor incidence and some of these tumors were found in the large intestine (Wasan et al., 1997; Yang et al., 1998) . Consistent with this observation, mice on low fat, high ®ber diets had reduced incidence of polyp formation (Hioki et al., 1997) . Since the mice are on a uniform genetic background and their dietary composition can be regulated, it would now be possible to de®nitively address gene-environment interactions in these models.
There are genes modifying the cancer susceptibility of Apc mutant mice. The most established one is the modi®er of Min locus (Mom1) (Dietrich et al., 1993) . Combination of Min and Mom1 leads to an increase of lifespan and reduced tumor number. The Mom1 gene encodes a secretory phospholipaseA2 (MacPhee et al., 1995) . For more information about this and other modi®ers we refer the interested readers to an article by Dove and colleagues in this issue.
Mouse models for HNPCC
Hereditary nonpolyposis colorectal cancer is characterized by an autosomal dominant mode of inheritance, high penetrance and an early onset of tumorigenesis. Up to 5% of all colorectal cancers in the United States are diagnosed as HNPCC. Although the predominant form of cancer in HNPCC is colorectal carcinoma, extracolonic cancers are often observed. The most frequent among them are endometrial cancer, ovarian cancer, cancer of the stomach and the small intestine as well as cancers of the upper renal tract. Based on the tumor spectrum, HNPCC is classi®ed into two susceptibility syndromes: Lynch I, if only colorectal (Lynch and Smyrk, 1996) .
Most cases of HNPCC are linked to mutations in genes of the bacterial mutS and mutL gene family. These genes encode proteins, which are homologues of the bacterial post replicative DNA mismatch repair (MMR) proteins MutS and MutL. Mutations in the human hMSH2 (mutS homologue) and hMLH1 (mutL homologue) are among the most commonly found mutations in HNPCC (reviewed by Kolodner, 1996) . Mutations in these genes lead to a signi®cantly higher mutation rate and MMR defective cells rapidly acquire mutations throughout their genome. This molecular phenotype is also termed RER (replication error phenotype) and cells that are defective in MSH2 or MLH1 are classi®ed as RER + . The RER + phenotype re¯ects the inability to repair small insertions and deletions. A common diagnostic method for scoring the RER + phenotype in tumors is to examine the alterations in the length of short microsatellite sequences present throughout the genome.
Most of our understanding about the mismatch repair system is derived from studies of the E. coli MutHLS system (reviewed in Modrich, 1991) . In bacteria, mismatches that are introduced during DNA replication are ®rst recognized by the MutS protein. The MutS protein bound to a base mispair is then recognized by the MutL protein. The interaction with MutS results in the activation of a third protein MutH. MutH is an endonuclease that introduces nicks into hemimethylated DNA on the unmethylated DNA strand. The combined action of all three proteins directs the repair of mismatches to the newly synthesized DNA strand. This system works in a bi-directional way, and mismatches of up to four base pairs are eciently repaired.
The mismatch repair system in eukaryotes is more complex, and several mutS and mutL homologues have Figure 2 Model for eukaryotic mismatch repair been found (reviewed in Kolodner, 1996; Modrich and Lahue, 1996) . Genetic studies in S. cerevisisae led to the identi®cation of six mutS homologues. The ®rst mutS homologue MSH1 that was identi®ed in yeast seems to be involved in the repair of mutations in the mitochondrial genome. Three of the other mutS homologues MSH2, MSH3 and MSH6 are required for the initiation of MMR in mitosis. MSH4 and MSH5 are not involved in mitotic MMR but have a role in the control of recombination processes during meiosis. With the exception of MSH1 human and mouse homologues of MSH2, MSH3, MSH4, MSH5 and MSH6 have been identi®ed.
Genetic and biochemical studies in yeast and human tumor cell lines have indicated that DNA mismatch repair is initiated by two dierent complexes: A complex between MSH2 ± MSH6 for the recognition of single base mismatches and a complex between MSH2 ± MSH3 for the recognition of two to four base pair insertion/deletions. The repair of mispaired bases is also dependent on homologues of the mutL gene product (Boyer et al., 1995; Li and Modrich, 1995; Umar et al., 1994; Drummond et al., 1995) . At least two of the yeast and human mutL homologues are implicated in mitotic mismatch repair. A stoichiometric complex between MLH1 and another mutL homologue PMS1 (PMS2 in humans) (Post Meiotic Segregation) that interacts with MSH2 bound to a base mispair is necessary for mismatch repair (Prolla et al., 1994a,b) . Not much is known about the subsequent steps leading to the excision of the mispaired base(s) and the resynthesis of the degraded DNA strand. Recently the 3'-5' exonuclease EXO1 was identi®ed in a two hybrid screen due to its interaction with MSH2 (Tishko et al., 1998; Schmutte et al., 1998) . In a similar approach the interaction between PCNA and MSH2/MLH1 was demonstrated indicating a link between MMR and replication processes . An overview over the eukaryotic mismatch repair is provided in Figure 2 .
Several genes implicated in mismatch repair were mutated in mice. The phenotypes in these mice are summarized in Table 2 .
MSH2 was the ®rst gene to be implicated in HNPCC (Fishel et al., 1993) . It also was also one of the ®rst HNPCC genes to be inactivated in mice (de Wind et al., 1995; Reitmair et al., 1995) . Msh2 de®cient mice are fertile and develop normally. Msh2 homozygous mutant mice have a reduced life span, compared to wild-type and heterozygote mutant animals. Fifty per cent of the animals die by the age of 6 months and all animals were reported dead by 12 months of age (Reitmair et al., 1996b) . These animals succumb to T-cell lymphomas early in their life and it has been suggested that Msh2 de®cient mice might serve as an animal model for lymphoblastic lymphomas (Lowsky et al., 1997) . In addition, MSH2 de®cient mice that survive more than 6 months of age develop GI and skin tumors. The GI-tumors found in these studies were classi®ed as adenomas and carcinomas. In one study the early lethality caused by lymphomas was suppressed by introduction of the Tap1 mutation into the MSH2 de®cient background (de Wind et al., 1998) . Tap1 homozygous mutant mice are immuno-compromised and lack CD8+T cells. Double mutant Tap17/7Msh27/7 mice do not develop lymphomas but develop GI and skin tumors. These results show that MSH2 de®cient mice can serve as a model for HNPCC, especially when combined with lymphoma suppressing mutations or agents.
Targeted mutagenesis of the Msh6 gene has revealed interesting results. Mice de®cient for MSH6 are fertile and develop a cancer susceptibility syndrome similar to Msh2 mutant mice . A majority of these mice develop invasive B and T cell lymphomas and GI tumors within their ®rst year of age. A dierence between Msh67/7 and Msh27/7 mice is the longer survival of the Msh67/7 mice. Fifty per cent of the Msh67/7 animals die by 10 to 11 months of age and all of the animals are dead by 18 months of age. Another surprising dierence between Msh27/7 and Msh67/7 mice is the lack of MI in Msh6 tumors. The molecular basis for this phenomenon became clear when the mismatch repair capability was investigated in a biochemical MMR assay. These tests revealed that although MSH6 de®cient extracts are unable to repair single base pair mismatches, they are able to repair insertion/deletion mismatches of one to four base pairs. As a consequence, the defective MMR in MSH6 de®cient tumors does not result in a RER+ phenotype. This observation has important implications because an involvement of MSH6 in HNPCC (Prolla et al., 1998) might not have been identi®ed if the RER+ phenotype is used as a diagnostic criterion. Families with germ line mutations in the MSH6 gene have been identi®ed Edelmann et al., 1997; Miyaki et al., 1997) . Tumors that are similar to those observed in Msh67/7 mice were found in some HNPCC patients. The tumors derived from some of these patients exhibit low level MI as predicted by the mouse study . These results reveal that MSH6 mutations lead to an attenuated form of HNPCC and may be the cause for some forms of non-classical HNPCC. MSH2 and MSH6 are involved in the repair of one base pair mismatches or insertions/deletions and both are associated with cancer susceptibility syndromes. Less is known about the involvement of the third protein, MSH3, in cancer susceptibility syndromes. Until now there is no evidence of an inherited mutation of human MSH3 in HNPCC cases. The fact that a complex of MSH2 ± MSH3 is necessary to initiate the repair of two to four nucleotide mismatches makes it necessary to study its role in tumorigenesis. To study such an involvement a null mutation in the mouse Msh3 gene was generated. MSH3 de®ciency in mice does not lead to a decreased survival rate or increased cancer susceptibility, a phenotype that is dierent than that observed in MSH2 and MSH6 de®cient mice (Edelmann et al., submitted for publication).
Targeted inactivation of the mutL homologue, Mlh1, in mice leads to infertility and tumor susceptibility (Edelmann et al., 1996 (Edelmann et al., , 1999b Baker et al., 1996; Prolla et al., 1998) . Mlh17/7 mice do not produce any mature sperm due to a pachytene arrest in meiosis. Mlh1 de®cient females do not produce fertile eggs. Analysis of spermatocytes in Mlh17/7 males revealed that the chromosomes are able to pair during pachytene but that meiosis is unable to proceed past that stage. The pachytene-arrested cells enter an apoptotic pathway.
Mlh17/7 mice have a reduced survival similar to Msh27/7 animals. Fifty per cent of the MLH1 de®cient animals die prior to 6 months of age and all animals die by 13 months of age. The decrease in survival is caused by the development of T cell lymphomas and gastrointestinal tumors. The GI tumors were found throughout the small intestine and range from adenomas to early invasive carcinomas (Edelmann et al., 1999b) . Typically one to two GI tumors were found per mouse. The Mlh1 tumors displayed a RER+ phenotype. Recently human MLH1 kindred that carried a homozygous MLH1 mutation were reported (Wang et al., 1999; Ricciardone et al., 1999) . These patients died at a very young age and developed leukemias and/or lymphomas and neuro®bromatosis type I. Although the presence of two mutant alleles in one human is extremely rare, the ®ndings suggest that defects in Mlh1 causes similar phenotypes in humans and mice.
A combination of Mlh1 and Apc1638N mutant mice showed a dramatic decrease of viability (Edelmann et al., 1999b) . No mice survived beyond 4 months of age. The tumor number in the double mutant mice increased to 45 tumors per mouse exclusively within the GI-tract. Although most of the tumors were classi®ed as adenomas, a signi®cant number of tumors had progressed to early invasive adenocarcinomas and late stage carcinomas (Figure 3) . Moreover, it was found that in tumor cells derived from the double mutants the wild-type APC protein was lost (Figure 1 ). Mutation analysis of the wild-type Apc allele in tumor samples revealed the presence of frequent frameshift mutations and base transitions. Many of these alterations were found within short repeated sequences within the Apc coding region. These data strongly suggest that the inactivation of APC is an important event for the development of RER+ tumors in the mouse. This is similar to ®ndings in human RER+ tumors and indicates that Mlh1/Apc1638N mice might serve as an excellent model for HNPCC.
A similar combination of a gene mutated in HNPCC and Apc Min has been generated. Mice (Reitmair et al., 1996a) . These mice showed a decreased lifespan, as compared to Apc Min or Msh2, and a higher number of adenomas, which developed more rapidly. The wild-type APC protein was absent in all adenomas analysed, as determined by immuno histochemical analysis.
Male mice de®cient for PMS2 are infertile but female mice have normal fertility (Baker et al., 1995) . The meiotic phenotype in PMS2 de®cient mice diers from that of MLH1 de®cient mice in that chromosomal asynapsis and non homologous pairing are frequent events in meiosis I of Pms27/7 mice. Pms27/7 mice are susceptible to the development of lymphomas and some rarer types of tumors (Prolla et al., 1998) . Cell lines derived from these mice display MI at both mono-and dinucleotide repeat loci. Interestingly Pms27/7 mice do not develop GI tumors. In combination with the Min Apc allele, Pms27/7 mice showed an increased number of tumors in the GI-tract compared to Min, but no change in the histology of the tumors was reported . This diers from the ®ndings in the Mlh1/Apc1638N mice where a greater percentage of tumors progressed to invasive carcinomas (Edelmann et al., 1999b) . This discrepancy could be attributed to a more speci®c function of Pms2 in MMR or to the high tumor load of mice carrying the Min allele, resulting in too short a lifespan to develop adenocarcinomas.
For some mutS and mutL proteins no role in mitotic MMR has been determined. The mutS homologues Msh4 and Msh5 are implicated in meiosis. Mutations in these genes reveal a requirement in prophase I of meiosis for chromosome pairing (Edelmann et al., 1999a and B Kneitz, unpublished) . Mutations in the MutL homologue Pms1 do not result in a tumor phenotype (Prolla et al., 1998) and its function is yet to be determined.
Other mouse models for CRC SMAD4 is a tumor suppressor deleted in pancreatic cancer and juvenile polyposis syndrome (Hahn et al., 1996; Howe et al., 1998) . In mice, inactivation of the Smad4 gene leads to embryonic lethality. Heterozygous mice do not display a cancer phenotype up to 1 year of age (Sirard et al., 1998) . If a Smad4 mutation is combined with an Apc mutation, it was shown that the progression was enhanced and the endpoint of tumorigenesis was more malignant (Takaku et al., 1998) . These results show a function for the TGF-b signaling during tumorigenesis in progression, rather than initiation.
A new tumor suppressor gene, PTEN, was found to cause inherited hamartoma cancer syndromes (Li et al., 1997; Eng and Peacocke, 1998) . Inactivation mutation in mice reveal a necessary function for Pten during embryogenesis, but a percentage of heterozygous mice also show colonic carcinomas (Di Cristofano et al., 1998; Suzuki et al., 1998) .
Mutations in the mouse homologue of the Drosophila caudal gene, Cdx2, leads to adenomas in the heterozygous state (Chawengsaksophak et al., 1997) . In humans, mutations in the CDX2 gene and LOH seem to play only a minor role in CRC (Wicking et al., 1998; Yagi et al., 1999) .
The Mcc and Dcc gene mutations, whose human counterparts are implicated in CRC, do not show a cancer susceptibility phenotype (Fazeli et al., 1997; Velcich et al., 1999) . Dcc, although implicated in apoptosis, has yet to show a physiological function in the GI tract, with its ligand being expressed in the brain. An inactivating Mcc mutation in the mouse also fails to show a cancer phenotype, but homozygous mice display a slightly higher proliferation rate of the epithelial crypt cells (Edelmann et al., unpublished) .
Epigenetic events such as methylation play an important role in tumorigenesis. It was shown that mice carrying a mutation in the DNA methylase and the Apc gene showed a decreased tumor load (Laird et al., 1995) . Another striking example is the inactivation of one MLH1 allele by methylation in a human tumor (Herman et al., 1998) .
Mouse models for colorectal cancer: present and future
In humans there is a sequence of genetic events that are thought to promote tumorigenesis from epithelial cells to carcinomas. In mouse, modeling this pathway has only partially been successful. Mutations in tumor suppressor genes such as APC lead to intestinal cancer. The role of oncogenes such as Ki-RAS has not yet been recapitulated in mice.
Mice provide some unique opportunities for the study of GI cancer. In humans, epidemiological studies have shown a role for genetic modi®ers as well as diet in the progression of CRC. Mice provide unique opportunities to de®ne and identify genes that are involved in these processes. The genetic de®nition and the cloning of the Mom1 gene as a modi®er of GI cancer in mice provides one example of the power of mouse genetics. The ability to develop congenic lines of mice with dierent Apc or MMR gene mutations would enable identi®cation of other genes that have a tumor modi®er role. Three reports showed that diet can modulate the tumor susceptibility phenotype in Apc mutant mice. Similar studies with mice carrying MMR gene mutations will help to identify the role of environmental factors on cancer. An interesting feature of the studies is that it is now possible to alter individual components of mouse diet (e.g. fat content) and ascertain how such alterations aect tumor susceptibility in dierent genetically modi®ed mice in dierent genetic backgrounds.
Much of the attention to-date in colorectal tumor susceptibility was focused on tumor initiation events. The availability of reliable mouse models for initiation now allows us to focus on genes involved in progression of cancer. Studies of progression require a better understanding of genetic and gene expression changes in cells at dierent stages of progression. Using an approach, referred to as SAGE, Vogelstein and colleagues identi®ed several genes whose expression patterns were altered in tumor cell lines (Zhang et al., 1997) . The availability and use of gene microarrays (Schena et al., 1996) are expected to yield new information about other genes that are involved in tumor progression. Such genes, in turn, are candidates for modi®cation in mice.
